Summary
A series of eight human ovarian cancer lines grown in nude mice were used to compare the activity of hexamethylmelamine (HMM) and N 2,N 4,N 6-trihydroxy methyl-N 2,N 4,N 6-trimethylmelamine (trimelamol). The tumor lines differed in histological subtype and growth rate. The drugs were administered i.p. at the maximum tolerated dose at alternate days. Differences in volume of treated and control tumors were endpoints of the study. The tumor lines varied widely in sensitivity to HMM and in four lines a T/C% below 25% was achieved. Trimelamol appeared to be more active than HMM and achieved a T/C below 25% in seven tumor lines. Thus far, the drug has demonstrated significant activity in a phase I trial in ovarian cancer patients. Comparative clinical studies of HMM vs trimelamol have not yet been performed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ames MM, Sanders ME, Tiede WS (1981) Metabolic activation of hexamethylmelamine and pentamethylmelamine by live microsomal preparations. Life Sci 29: 1591
Bonomi PD, Mladineo J, Morrin B, Wilbanks G, Slayton RE (1979) Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents. Cancer Treat Rep 63: 137
Boven E, Van der Vijgh WJF, Nauta MM, Schlüper HMM, Pinedo HM (1985) Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res 45: 86
Boven E, Nauta MM, Schlüper HMM, Elferink F, Van der Vijgh WJF, Pinedo HM (1985) Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice. Eur J Cancer Clin Oncol 21: 1253
Buckley SM, Stock CC, Crossley ML, Rhoads CP (1952) Inhibition of the Crocker mouse sarcoma 180 by certain ethylenimine derivatives and related compounds. Cancer 5: 144
Casper ES, Gralla RJ, Lynch GR, Jones BR, Woodcock TM, Gordon C, Kelsen DP, Young CW (1981) Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion. Cancer Res 41: 1402
Connors TA, Cumber AJ, Ross WCJ, Clarke SA, Mitchley BCV (1977) Regression of human lung tumor xenografts induced by water-soluble analogs of hexamethylmelamine. Cancer Treat Rep 61: 927
Cumber AJ, Ross WCJ (1977) Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility. Chem Biol Interact 17: 349
D'Incalci M, Bolis G, Mangioni C, Morasca L, Garattini S (1978) Variable oral absorption of hexamethylmelamine in man. Cancer Treat Rep 62: 2117
Eva A, Robbins KC, Andersen PR, Srinivasan A, Tronick SR, Reddy EP, Ellmore NW, Galen AT, Lautenberger JA, Papas TS, Westin EH, Wong-Staal F, Gallo RC, Aaronson SA (1982) Cellular genes analogous to retroviral one genes are transcribed in human tumour cells. Science 295: 116
Goldberg RS, Griffin JP, McSherry JW, Krakoff IH (1980) Phase I study of pentamethylmelamine. Cancer Treat Rep 64: 1319
Johnson BL, Fisher RI, Bender RA, DeVita VT, Chabner BA, Young RC (1978) Hexamethylmelamine in alkylating agentresistant ovarian carcinoma. Cancer 42: 2157
Judson IR, Rutty CJ, Abel G, Gumbrell L, Harrap KR, Calvert AH (1985) Report on the Phase I trial of N 2,N 4,N 6-trihydroxymethyl-N 2,N 4,N 6-trimethylmelamine (trimelamol). Br J Cancer 52: 466
Klippert PJM, Hulshoff A, Mingels MJJ, Hofman G, Noordhoek J (1983) Low oral bioavailability of hexamethylmelamine in the rat due to simultaneous hepatic and intestinal metabolism. Cancer Res 43: 3160
Legha SS, Slavik M, Carter SK (1976) Hexamethylmelamine. An evaluation in its role in the therapy of cancer. Cancer 38: 27
Muindi JRF, Newell DR, Smith IE, Harrap KR (1983) Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies. Br J Cancer 47: 27
Neyt JP, Ten Bokkel Huinink WW, van der Burg MEL, Van Oosterom AT, Vriesendorp R, Kooyman CD, Van Lindert ACM, Hamerlynck JVTH, Van Lent M, Van Houwelingen JC, Pinedo HM (1984) Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 2: 594
Rutty CJ, Newell DR, Muindi JRF, Harrap KR (1983) The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse. Cancer Chemother Pharmacol 8: 105
Van Echo DA, Chiuten DF, Whitacre M, Aisner J, Lichtenfeld JL, Wiernik PH (1980) Phase I trial of pentamethylmelamine in patients with previously treated malignancies. Cancer Treat Rep 64: 1335
Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, DeVita VT (1978) Advanced ovarian carcinoma. A prospective clinical trial of melphalan (L0PAM) versus combination chemotherapy. N Engl J Med 299: 1261
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boven, E., Nauta, M.M., Schlüper, H.M.M. et al. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts. Cancer Chemother. Pharmacol. 18, 124–128 (1986). https://doi.org/10.1007/BF00262280
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262280